[Treatment perspectives].
Celiac disease (CD) is a chronic inflammatory enteropathy caused by the ingestion of gluten. A safe and efficient but unpleasant treatment exists for CD in form of a strict gluten-free diet. Thus, there is a need for new treatment strategies, which are based on the improved and advanced understanding of the pathophysiology of CD. The first strategy consists in reducing or even eliminating major antigenic motifs in gluten, responsible for the inflammatory reaction. The use of less immunogenic wheat was suggested but this seems rather difficult to realize. However, a complete digestion of the immunogenic parts of gluten looks very promising. This can be obtained by the use of polymers, capable to sequester gluten proteins or even better via the exogenous administration of propyl-endopeptidases, with two different enzymes under development. Another approach could be the use of inhibitors of tissue transglutaminase, a strategy which is under clinical investigation. Alternatively, inhibition of the site of liaison of immunostimulatory peptides with HLA molecules was suggested and is also under investigation in vivo. For patients suffering from refractory sprue, the inhibition of IL15 might be of therapeutic interest with the hope to improve the fatal outcome of many of these patients. However, the ultimate treatment approach is in form of prevention and the role of infectious agents, such as Rotavirus, in disease onset has to be considered.
Université Paris Descartes, 75006 Paris, France.
H
H
Garnier-Lengliné
G
G
Malamut
N
N
Cerf-Bensussan
F M
FM
Ruemmele
D002446:Celiac Disease / Q000517:prevention & control / Q000628:therapy*; D055050:Diet, Gluten-Free / Q000379:methods; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D019204:GTP-Binding Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy; D010455:Peptides / Q000627:therapeutic use; D030821:Plants, Genetically Modified; D011315:Preventive Medicine / Q000379:methods / Q000639:trends; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D035703:Therapies, Investigational / Q000379:methods / Q000639:trends; D011503:Transglutaminases / Q000037:antagonists & inhibitors; D014908:Triticum / Q000235:genetics
D004791:Enzyme Inhibitors; D010455:Peptides; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins